Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AEYE +3.1% (acquires ADA Site Compliance; raises Q3 and FY24 outlook)
Other news:
- BWAY +15.6% (enters $20 mln private placement with Valor Equity Partners)
- NIO +13.2% (enters RMB3.3 bln investment in NIO China from strategic investors)
- PRME +11% (strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) to develop reagents for the next generation of ex vivo T-cell therapies)
- BGNE +9.4% (updates and restates the risk factors discussed)
- MNKD +3.5% (announced top-level 30-week results from its Phase 4 INHALE-3 study)
- ALT +3.4% (completes enrollment in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis)
- ELVN +2.7% (reports Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia)
- DTIL +2.7% (Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B)
- LEGN +2.2% (CARVYKTI is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line)
- ACET +2.1% (Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases)
- MESO +2% (enters option to issue up to $50 million convertible notes for product launch)
- LPTX +1.9% (Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients)
- KEN +1.5% (announces updates in Israel Land Authority tender to design and build electricity generation facilities using photovoltaic technology)
- AURA +1.4% (CFO Julie Feder to depart, effective October 25; Amy Elazzouzi, VP, Finance, appointed interim CFO)
- GOGO +1.4% (enters into definitive agreement to acquire Satcom Direct for $375 mln in cash and five mln shares of Gogo stock at closing)
- OGN +1% (primary endpoint met in phase 3 comparative clinical study of Perjeta biosimilar candidate HLX11)
- BCRX +1% (wins $69 mln RAPIVAB (peramivir injection) contract from US Government)